Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 0.41 |
| ▸ | JAK3 | P52333 | 12/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 5/20 | 0.40 |
| ▸ | TYK2 | P29597 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7883835 | 0.91 | TYK2 (0.41) | JAK1JAK3RIPK2PDE4BJAK2 | |
| SCHEMBL17604090 | 0.89 | RIPK2 (0.46) | JAK1JAK3RIPK2JAK2TYK2 | |
| SCHEMBL19434450 | 0.88 | PDE4B (0.39) | JAK1JAK3PDE4BJAK2TYK2 | |
| SCHEMBL19434460 | 0.88 | PDE4B (0.41) | JAK1JAK3PDE4BJAK2TYK2 | |
| SCHEMBL19434489 | 0.87 | PDE4B (0.38) | JAK1JAK3PDE4BJAK2TYK2 | |
| SCHEMBL1717428 | 0.86 | RIPK2 (0.44) | JAK1JAK3RIPK2JAK2TYK2 | |
| SCHEMBL1164192 | 0.86 | RIPK2 (0.44) | JAK1JAK3RIPK2JAK2TYK2 | |
| SCHEMBL6346129 | 0.85 | RIPK2 (0.41) | JAK1JAK3RIPK2JAK2TYK2 | |
| SCHEMBL2078467 | 0.84 | RIPK2 (0.43) | JAK1JAK3RIPK2JAK2TYK2 | |
| SCHEMBL19434566 | 0.84 | PDE1B (0.37) | JAK1JAK3PDE4BJAK2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025245472-A1 | COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-3529250-B1 | IMIDAZOPYRAZINONES, PYRAZOLOPYRIMIDINONES AND PYRAZOLOPYRIDINONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2023-12-06 | — | — | EP | disclosed |
| CN-109843884-B | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | H.隆德贝克有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-109071549-B | PDE1 inhibitors | H.隆德贝克有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210130362-A1 | MEDICAL USE OF COMPOUND III | BOEHRINGER INGELHEIM INT (DE) | 2021-05-06 | — | — | US | disclosed |
| US-10919898-B2 | Medical use of compound III | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
| EP-3442975-B1 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| EP-3442975-B1 | 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2020-07-29 | — | — | EP | disclosed |
| US-10633382-B2 | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-04-28 | — | — | US | disclosed |
| US-10633382-B2 | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-04-28 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010084438-A1 | AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS | PFIZER INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2009121919-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919898-B2 | Medical use of compound III | PTGER3, SLC6A3, UGT1A3 | JAK1 2497/4885JAK3 240/4885RIPK2 3339/4885 |
| US-20210130362-A1 | MEDICAL USE OF COMPOUND III | PTGER3, SLC6A3, UGT1A3 | JAK1 2497/4885JAK3 240/4885RIPK2 3339/4885 |
| US-10633382-B2 | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors | PDE5A, PDE12, PDE3A | JAK1 306/4885JAK3 1078/4885RIPK2 2817/4885 |
| US-20100190771-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | JAK1 1249/4885JAK3 1813/4885RIPK2 4117/4885 |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | JAK1 1286/4885JAK3 1750/4885RIPK2 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.